Bharat Biotech’s Covaxin has shown 77.8 per cent efficacy against coronavirus in the phase 3 trials, ANI cited sources as saying.
India’s first indigenous vaccine, Bharat Biotech has developed Covaxin with National Institute of Virology and Indian Medical Research Center. It is one of the three vaccines being administered under country’s nationwide vaccination programme. The vaccine was granted emergency use authorisation in December last year. Centre’s decision to approve the vaccine candidate without its complete trials still attracts flak.
Meanwhile, efficacy rate came out on Tuesday after DGCI’s subject expert committee (SEC) met and discussed the results.
The pharmaceutical firm had submitted phase 3 trial data for the vaccine to the Drug Controller General of India (DGCI) over the weekend.
Bharat Biotech is also expected to hold a ‘pre-submission’ meeting on Wednesday with the World Health Organization for international emergency use listing (EUL) of its vaccine.
